Last mentioned: Mar 21, 2026
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Court Ruling
Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
Settlement Reached
Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
Legal Challenge
The AAP and ACP file suit in Massachusetts federal court to block the changes.
Thursday Pre-Market
Key reports from Moderna, Newmont, Keurig Dr Pepper, Cheniere Energy, and Viatris.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
FDA U-Turn
Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Regulatory U-Turn
The FDA officially agrees to consider the application after resolving the internal and public dispute.
Wednesday Pre-Market
Key reports from Analog Devices, Kraft Heinz, Garmin, Wix.com, and Wingstop.
Public Dispute
Moderna and administration officials engage in a public disagreement over the regulatory path forward.
Public Dispute
Reports emerge that career FDA scientists were overruled, leading to a public standoff between Moderna and the agency.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
Initial Rejection
Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
Initial Rejection
Trump administration vaccine chief refuses to review Moderna's mRNA flu shot application.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
Initial BLA Submission
Moderna submits its Biologics License Application for mRNA-1010.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
ACIP Restructuring
HHS replaces existing ACIP members with figures aligned with the administration's views.
A federal judge has issued a temporary injunction against the vaccine policy agenda proposed by Robert F. Kennedy Jr., citing potential risks to public health infrastructure. While the ruling provides a reprieve for existing immunization standards, experts warn that the ongoing legal and political battle could further erode public confidence in scientific institutions.
A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Following the latest earnings cycle, Seeking Alpha's quantitative analysis identifies a significant performance gap between biopharma innovators and retail pharmacy giants. While Incyte and UnitedHealth lead with near-perfect scores, Walgreens and Moderna have fallen into 'Strong Sell' territory.
Wix and PAR Technology shares surged on March 4, 2026, signaling a robust appetite for e-commerce and unified commerce infrastructure. The rally, supported by broader gains in the SaaS sector including Cloudflare, highlights a shift toward high-margin digital enablement tools in the retail and restaurant landscapes.
Moderna (MRNA) shares rose significantly on March 4, 2026, as part of a broader market rally that lifted high-growth technology and clean energy stocks. The move highlights a renewed investor appetite for innovative platforms, signaling a potential recovery for the biotech sector following a period of macro-induced volatility.
A significant market rally on March 4, 2026, saw shares of Moderna, Wix, and Cloudflare surge as investors prioritized biotech innovation and the digital infrastructure powering modern healthcare delivery. These gains reflect a growing convergence between clinical breakthroughs and the secure, scalable platforms required to manage patient engagement at scale.
Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
A diverse slate of market leaders across semiconductors, consumer goods, and energy are set to report results, providing a critical pulse check on industrial demand and consumer spending. Key reports from Analog Devices, Moderna, and Kraft Heinz will highlight the divergent paths of the tech recovery and the healthcare sector's post-pandemic transition.
The FDA has agreed to review Moderna’s mRNA-based influenza vaccine after a high-profile rejection by the Trump administration's vaccine chief. The reversal follows a public dispute where scientific staff were reportedly overruled, marking a significant shift for the first-of-its-kind vaccine candidate.
Investors are navigating a complex Wednesday session as major players in biotech, semiconductors, and leisure release pivotal updates. Market attention is centered on Moderna's pipeline diversification and SanDisk's recovery in the memory sector, signaling a shift toward fundamental-driven trading.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
YieldMax has announced its latest round of monthly distributions for its suite of single-stock synthetic covered call ETFs, including those tracking MicroStrategy, Tesla, and Microsoft. The payouts reflect the varying volatility levels of the underlying assets, with MRNA and MSTR leading the distribution amounts.
The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.